Pharmacology & toxicology
3,020 studies240 in 7 days1,454 in 30 days
Filters
Latest
3,020 studies
- Multi-tissue accumulation of potentially toxic elements and age-stratified non-carcinogenic dietary risk in fish from the Anzali Wetland, Caspian Basin.
- Part 2 of a 2-part open-label clinical trial evaluating repeated nicotinamide riboside parenteral administration: 90 days of at-home subcutaneous injections
- Do drugs proposed to protect or harm joints change serious osteoarthritis events? A meta-analysis of adverse event tables from 881 randomized trials
- Placebo-Adjusted Frequencies of Nonserious Adverse Reactions Listed on US Prescription Drug Labels
- From therapeutic landscape perception to revisit intention: the mediating role of restorative experience in Palandöken Urban Forest
- Fifteen-year real-world pharmacovigilance of multiple sclerosis disease-modifying therapies: adverse event profiles, drug-specific safety signals and clinical implications
- Survey-based perspectives and reported barriers to DPYD testing among U.S. oncologists
- Real-world safety of vericiguat as a fifth-line agent in heart failure: a pharmacovigilance study of quintuple therapy
- Age-stratified reporting of immune checkpoint inhibitor-associated myocarditis: disproportionality is amplified in older adults, with implications for geriatric oncology
- Mechanisms of traditional Chinese medicine interventions in the gastric ‘inflammation-to-carcinoma’ cascade: advances in in vitro models from monolayer cells to organoids
- Phenotype-informed selection of microbiota-directed interventions in irritable bowel syndrome: current evidence and limitations
- Faricimab 6 mg versus aflibercept 8 mg in diabetic macular oedema: an in silico study of anchored efficacy and common-protocol treatment burden
- Short-term superiority in proteinuria control with exploratory longitudinal trajectories: finerenone-dapagliflozin combination in non-diabetic kidney disease
- Conditional approval of oncology medicines in Europe (2017–2022): evidence maturity, regulatory outcomes, clinical benefit and downstream access
- Evaluating student perceptions of image-based audience response questions in medical education
- Economic evaluation of six immune checkpoint inhibitor-based first-line therapies for advanced squamous non-small-cell lung cancer: a cost-effectiveness analysis based on network meta-analysis
- The association between air pollution exposure during pregnancy and low birth weight: a retrospective cohort study in southern China
- Long-term exposure to ambient air pollution mixtures and incident cardiovascular–liver–metabolic multimorbidity: a prospective cohort study
- A base-editing and auxotrophic selection platform for linking epigenetic regulators to silent biosynthetic gene clusters in Aspergillus nidulans.
- Untargeted metabolomics and antioxidant responses reveal tissue- and species-specific metabolic profiles in three Epimedium species
- Non-PML neuroinvasive infections reported with multiple sclerosis disease-modifying therapies: a mechanism-based pharmacovigilance study, 2004–2025
- Acid-responsive nanoparticles with microneedles for anti‑inflammatory sonodynamic therapy of gouty arthritis.
- CPR-Centered Redox Interactions Between Cytochrome P450 Oxidoreductase and Cytochrome c Oxidase: Potential Pharmacological Implications
- Exploring Bacteria from Extreme Environments in Chilean Patagonia for Antitrypanosomal Metabolites
- Discovery of a Peripherally Directed CB1 Receptor Antagonist That Restores Insulin Signaling in Adipocytes